Ta Hsung Tung

Array ( [id] => 13106897 [patent_doc_number] => 10072081 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-09-11 [patent_title] => Anti-CTLA4, anti-GLUT2 protein for the treatment of type 1 diabetes [patent_app_type] => utility [patent_app_number] => 14/943852 [patent_app_country] => US [patent_app_date] => 2015-11-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 17 [patent_figures_cnt] => 17 [patent_no_of_words] => 23111 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 134 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14943852 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10822083 [patent_doc_number] => 20160168248 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-06-16 [patent_title] => 'Regulatory T Cell Mediator Proteins and Uses Thereof' [patent_app_type] => utility [patent_app_number] => 14/940940 [patent_app_country] => US [patent_app_date] => 2015-11-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 25 [patent_figures_cnt] => 25 [patent_no_of_words] => 49326 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14940940 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11205166 [patent_doc_number] => 09434785 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2016-09-06 [patent_title] => 'Anti-human OX40L antibodies and methods of treating graft versus host disease with the same' [patent_app_type] => utility [patent_app_number] => 14/935937 [patent_app_country] => US [patent_app_date] => 2015-11-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 16 [patent_no_of_words] => 86443 [patent_no_of_claims] => 30 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 109 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14935937 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11415271 [patent_doc_number] => 09562087 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-02-07 [patent_title] => 'High affinity PD-1 agents and methods of use' [patent_app_type] => utility [patent_app_number] => 14/931725 [patent_app_country] => US [patent_app_date] => 2015-11-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 36 [patent_figures_cnt] => 52 [patent_no_of_words] => 45235 [patent_no_of_claims] => 30 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 67 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14931725 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15784939 [patent_doc_number] => 10626176 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-04-21 [patent_title] => Methods of treating conditions with antibodies that bind B7-H4 [patent_app_type] => utility [patent_app_number] => 15/522061 [patent_app_country] => US [patent_app_date] => 2015-10-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 27 [patent_figures_cnt] => 26 [patent_no_of_words] => 30334 [patent_no_of_claims] => 2 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 167 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15522061 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10784192 [patent_doc_number] => 20160130348 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-05-12 [patent_title] => 'ANTIBODIES AND OTHER MOLECULES THAT BIND B7-H1 AND PD-1' [patent_app_type] => utility [patent_app_number] => 14/926732 [patent_app_country] => US [patent_app_date] => 2015-10-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 19 [patent_figures_cnt] => 19 [patent_no_of_words] => 40408 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14926732 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10799187 [patent_doc_number] => 20160145344 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-05-26 [patent_title] => 'MURINE AND HUMAN INNATE LYMPHOID CELLS AND LUNG INFLAMMATION' [patent_app_type] => utility [patent_app_number] => 14/918277 [patent_app_country] => US [patent_app_date] => 2015-10-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 19 [patent_figures_cnt] => 19 [patent_no_of_words] => 12445 [patent_no_of_claims] => 23 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14918277 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14667613 [patent_doc_number] => 10371702 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-08-06 [patent_title] => Detection and treatment of autoimmune disorders [patent_app_type] => utility [patent_app_number] => 14/874851 [patent_app_country] => US [patent_app_date] => 2015-10-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 21 [patent_figures_cnt] => 39 [patent_no_of_words] => 13964 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 47 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14874851 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10663639 [patent_doc_number] => 20160009784 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-01-14 [patent_title] => 'Chimeric Receptors with 4-1BB Stimulatory Signaling Domain' [patent_app_type] => utility [patent_app_number] => 14/872947 [patent_app_country] => US [patent_app_date] => 2015-10-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 21080 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14872947 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11713662 [patent_doc_number] => 20170182161 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-06-29 [patent_title] => 'Antigen Binding Proteins that Bind PD-L1' [patent_app_type] => utility [patent_app_number] => 14/864677 [patent_app_country] => US [patent_app_date] => 2015-09-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 16 [patent_figures_cnt] => 16 [patent_no_of_words] => 49442 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14864677 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10656190 [patent_doc_number] => 20160002334 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-01-07 [patent_title] => 'BI-SPECIFIC ANTIBODIES AGAINST TIM-3 AND PD-1 FOR IMMUNOTHERAPY IN CHRONIC IMMUNE CONDITIONS' [patent_app_type] => utility [patent_app_number] => 14/857402 [patent_app_country] => US [patent_app_date] => 2015-09-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 13 [patent_no_of_words] => 39519 [patent_no_of_claims] => 1 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14857402 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10813751 [patent_doc_number] => 20160159910 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-06-09 [patent_title] => 'ANTI-B7-H4 ANTIBODIES AND IMMUNOCONJUGATES' [patent_app_type] => utility [patent_app_number] => 14/851003 [patent_app_country] => US [patent_app_date] => 2015-09-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 42 [patent_figures_cnt] => 42 [patent_no_of_words] => 77075 [patent_no_of_claims] => 100 [patent_no_of_ind_claims] => 18 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14851003 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13049263 [patent_doc_number] => 10046008 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-08-14 [patent_title] => Methods for treating chronic lymphocytic leukemia (CLL) [patent_app_type] => utility [patent_app_number] => 14/850542 [patent_app_country] => US [patent_app_date] => 2015-09-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 7 [patent_no_of_words] => 26474 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 155 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14850542 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13970485 [patent_doc_number] => 10214585 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-02-26 [patent_title] => Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS [patent_app_type] => utility [patent_app_number] => 14/850794 [patent_app_country] => US [patent_app_date] => 2015-09-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 20 [patent_figures_cnt] => 56 [patent_no_of_words] => 21054 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 129 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14850794 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11025162 [patent_doc_number] => 20160222117 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-08-04 [patent_title] => 'NUCLEIC ACID ENCODING ANTI-PD-L1 ANTIBODIES' [patent_app_type] => utility [patent_app_number] => 14/846457 [patent_app_country] => US [patent_app_date] => 2015-09-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 16 [patent_figures_cnt] => 16 [patent_no_of_words] => 66180 [patent_no_of_claims] => 85 [patent_no_of_ind_claims] => 13 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14846457 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11269234 [patent_doc_number] => 20160331781 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-11-17 [patent_title] => 'ACTIVATION OF MARROW INFILTRATING LYMPHOCYTES IN HYPOXIC ALTERNATING WITH NORMOXIC CONDITIONS' [patent_app_type] => utility [patent_app_number] => 15/112353 [patent_app_country] => US [patent_app_date] => 2015-09-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 13 [patent_no_of_words] => 6871 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15112353 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10750739 [patent_doc_number] => 20160096890 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-04-07 [patent_title] => 'B7-H1, A NOVEL IMMUNOREGULATORY MOLECULE' [patent_app_type] => utility [patent_app_number] => 14/845020 [patent_app_country] => US [patent_app_date] => 2015-09-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 31 [patent_figures_cnt] => 31 [patent_no_of_words] => 17765 [patent_no_of_claims] => 2 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14845020 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10750738 [patent_doc_number] => 20160096889 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-04-07 [patent_title] => 'B7-H1, A NOVEL IMMUNOREGULATORY MOLECULE' [patent_app_type] => utility [patent_app_number] => 14/844914 [patent_app_country] => US [patent_app_date] => 2015-09-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 31 [patent_figures_cnt] => 31 [patent_no_of_words] => 17762 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14844914 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10714197 [patent_doc_number] => 20160060344 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-03-03 [patent_title] => 'COMBINATION THERAPY FOR PD-L1 NEGATIVE TUMORS' [patent_app_type] => utility [patent_app_number] => 14/838650 [patent_app_country] => US [patent_app_date] => 2015-08-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 11 [patent_no_of_words] => 10638 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 9 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14838650 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12490614 [patent_doc_number] => 09994818 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-06-12 [patent_title] => ICOS critically regulates the expansion and function of inflammatory human Th17 cells [patent_app_type] => utility [patent_app_number] => 14/823281 [patent_app_country] => US [patent_app_date] => 2015-08-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 23 [patent_figures_cnt] => 13 [patent_no_of_words] => 23639 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 84 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14823281 [rel_patent_id] =>[rel_patent_doc_number] =>)